News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

American Society of Hematology: Novel Hodgkin Drug 'Dramatic' in Refractory Patients, City of Hope Study


12/7/2010 7:04:05 AM

MedPageToday -- ORLANDO -- In a phase II trial, an investigational drug for Hodgkin lymphoma had a "dramatic response rate" in a cohort of patients who had failed previous therapy, a researcher reported here. Three-quarters of the patients treated with brentuximab vedotin had at least some reduction in the tumor burden and more than a third had a complete remission, according to Robert Chen, MD, of City of Hope National Medical Center in Duarte, Calif.

Read at MedPageToday


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES